0 CHECKOUT

PRODUCT FILTERS

REGION

54
13
10
9
8

COUNTRY

6
3
2
2
2

CATEGORIES

  • 48
  • 27
  • 13
  • 12
  • 10
  • 9
  • 9
  • 6
  • 6
  • 6
  • 5
  • 5
  • 4
  • 4
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL

PRICE

47
51
64
161

PUBLISHED

1
19
46
161

PRODUCT TYPE

113
44
4

Search for: "AstraZeneca: Performance, Products, Pipeline and Potential"

AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review

AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the...

Published:  March 2016
Price:  From

Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line

Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease,...

Published:  September 2015
Price:  From

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

What Will the Pharma Industry Look Like in 5 Years? There are an estimated 724 projects in development from the top 50 pharmaceutical companies.  Together, they have the potential to add billions...

Published:  August 2012
Price:  From

Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

“Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities...

Published:  July 2015
Price:  From

Rare Diseases: The Pharmaceutical Landscape and Opportunity Areas

The service oriented and dynamic nature of the healthcare industry has led to the discovery of a plethora of treatment options for a wide range of ailments.However, there are certain diseases, termed...

Published:  March 2015
Price:  From

Diabetes - KOL Insight and Consensus Outlook Modules

The medium term: battle lines are drawn The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels of obesity and disease prevalence in both established...

Published:  September 2013
Price:  From

DPP IV Inhibitors - Global Strategic Business Report

This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million by the following drugs – Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors (including Linagliptin and...

Published:  September 2011
Price:  From

Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025

Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to...

Published:  July 2015
Price:  From

Pharmaceutical Products of the Future: 50-Company Pipeline Analysis to 2015

What Will The Pharmaceutical Market Look Like in the Next Five Years? In this report, Kalorama has analyzed the late stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies...

Published:  July 2010
Price:  From

Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025

Over decades, the oncology market has been led by surgery, chemotherapy and radiotherapy. The non-specificity of chemotherapy/radiotherapy and limitations of surgery has expanded the focus of many pharmaceutical...

Published:  April 2015
Price:  From

Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024

Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Generally addressed as the marriage of an antibody...

Published:  August 2014
Price:  From

Global Biopharma Outlook 2012 - Major US and EU Pharma

Global Biopharma Outlook 2012 –Major US and EU Pharma Unarguably 2011 was one of the very good years for the global Pharma industry as the USFDA approved a trend setting 39 new drugs, which is way ahead...

Published:  January 2012
Price:  From

Global Biopharma Outlook 2011: Major US and EU

The year 2011 and 2012 will be a bonanza for generic companies, as large innovator companies will lose patent exclusivity on prescription drugs worth over $70b in sales It is imperative to understand...

Published:  February 2011
Price:  From

Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches

This report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment...

Published:  January 2015
Price:  From

Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth

The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16 6 billion in 2012 to a projected value of $21 6 billion in 2019 This growth...

Published:  October 2013
Price:  From

World Anti-Inflammatory Therapeutics - Market Opportunities and Forecasts, 2014 - 2020

Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks...

Published:  June 2015
Price:  From

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to...

Published:  February 2016
Price:  From

Antibody Drug Conjugates Market (3rd Edition)

The “Antibody Drug Conjugates Market (3rd edition), 2015-2025” report provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of ADCs. The ADC market...

Published:  December 2015
Price:  From

RNAi Therapeutics Market, 2015 - 2030

Discovered less than two decades ago, RNAi has made its presence felt in all spheres of the pharmaceutical industry. RNAi is a natural post-transcriptional process of gene silencing involving short...

Published:  December 2015
Price:  From

Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Cangrelor (Acute Coronary Syndrome) - Forecast...

Published:  July 2014
Price:  From
Loading Indicator

Our Clients

  • Abbott Laboratories Ltd.
  • Ford Motor Company
  • Honeywell International, Inc.
  • Nike, Inc.
  • Deloitte LLP.
  • IMAX Corporation